Lock in an 11% yield with Sabre
Sabre, a best-in-class company is undervalued due to low profits in the motor insurance industry. Should you invest?

A good piece of advice for investors in general is to avoid the motor insurance industry. It has a terrible record when it comes to making money. Since 2008, the UK motor insurance industry has reported an average combined ratio of 104%.
A combined ratio is a key metric of profitability for the insurance sector. It tells us how much a company pays out in insurance claims compared with how much it receives from premiums. If the ratio is consistently above 100%, that’s not a good sign, as it means the company is consistently losing money on an underwriting (pure insurance) basis.
However, there are some gems in the sector – businesses that are very picky about whom they choose to insure. Admiral (LSE: ADM) is one of my favourite plays in the sector due to its diversified and international business model. Sabre Insurance (LSE: SBRE) had its issues amid a tough claims environment in 2023. A little over a year later, Sabre seems out of the woods, although the market does not seem to understand the potential opportunity.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sabre pushes through a tough industry
Unlike Admiral, a mass-market insurance group offering everything from car to home and travel insurance to personal loans, Sabre has a more focused business model. The company has three main business divisions: motor, motorcycle and taxi insurance. It provides insurance to drivers who may be unable to find coverage anywhere else, which means it targets a unique customer base and has much more flexibility on pricing compared with its mass-market peers.
That’s good news in a tough business that is going through a rough patch. The years 2022 and 2023 were some of the worst on record for the industry, with combined ratios of 111% and 112% respectively on average. It is still losing money, even though the average car insurance premium has risen from about £400 a year at the start of 2022 to £622 in the second quarter of 2024 – a rise of just under 60%, on average.
While premiums have risen 60% on average, the cost of repairing vehicles and personal injury claims has accelerated even faster. Analysts at Panmure Liberum have calculated that if insurance premiums accurately reflected claims inflation over the past four years, the average premium should be £849 per year, 36% above current levels.
Even then, the analysts warned, that would only take premiums back to 2012 levels in real terms (taking into account inflation in the price of car parts), and the industry didn’t make money in 2012.
This suggests the industry would have to hike average premiums to roughly £1,000 a year to be sustainably profitable. Considering how much flak the sector is already taking for pushing premiums up by nearly 60% over the past few years, further significant premium growth seems improbable.
It seems as if the industry has decided to start swallowing the losses – the data suggests that mass-market car insurance providers have started to reduce premiums. Sabre, on the other hand, hiked its prices by a double-digit percentage during the first nine months of 2024, according to its latest trading update, issued in mid-October. For the reasons outlined above, Sabre can push through growth while other companies fight for market share.
Should you invest in Sabre?
Sabre is focused on underwriting profitability and its profit-margin goals. As such, it will not write business that does not conform to its pricing model, whereas some of its peers may be willing to accept that risk. The firm knows its markets well, so it can price effectively without relying on guesswork or over-optimistic projections.
It’s this unique advantage that has enabled the company’s combined ratio to come in ahead of the rest of the UK motor insurance industry by 20 percentage points on average over the past decade, according to asset manager Berenberg’s analysis. In 2022, a historically bad year for the industry and a bad year for Sabre, the company still reported a combined ratio of 93.4%, significantly above its long-term average in the mid-70% range, but still profitable and better than the wider sector.
The company has substantial competitive advantages and unique qualities in a commoditised industry. However, Sabre’s current valuation does not seem to take these factors into account. The stock is currently trading at a price-to-earnings (p/e) multiple of 8.2, compared with its five-year historical average of 12.8 and peak of 18 times earnings, according to Panmure Liberum.
That could be something to do with the market capitalisation, which, at £350 million, is below the radar of most large fund managers. Investors have withdrawn tens of billions of pounds from UK small-cap funds over the past five years, depressing the valuation of small-caps and causing valuation distortions. Sabre seems to be a case in point.
It could be some time before these trends reverse, but it will pay investors to wait – the company has committed to returning the bulk of its earnings to shareholders via dividends. Berenberg believes that could translate into the company returning 43% of its current share price in dividends by 2027.
On an annualised basis, that suggests a dividend of 9.3% for 2024, 10.7% for 2025 and 11.4% for 2026, based on past underwriting profitability trends and the current solvency ratio, which sits at 85%, above the management target of 140% to 160%. Management has indicated it will return anything above this level to shareholders as surplus capital.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Rupert is the former deputy digital editor of MoneyWeek. He's an active investor and has always been fascinated by the world of business and investing. His style has been heavily influenced by US investors Warren Buffett and Philip Carret. He is always looking for high-quality growth opportunities trading at a reasonable price, preferring cash generative businesses with strong balance sheets over blue-sky growth stocks.
Rupert has written for many UK and international publications including the Motley Fool, Gurufocus and ValueWalk, aimed at a range of readers; from the first timers to experienced high-net-worth individuals. Rupert has also founded and managed several businesses, including the New York-based hedge fund newsletter, Hidden Value Stocks. He has written over 20 ebooks and appeared as an expert commentator on the BBC World Service.
-
8 of the best houses for sale with annexes
The best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
By Natasha Langan Published
-
Zelenskyy moves to appease Donald Trump – what happens now?
Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
By Emily Hohler Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fades
Food-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
By Dr Matthew Partridge Published
-
Should investors stay bullish and buy UK and US stocks?
Opinion Ignore the Eeyores, says Max King. The outlook for stocks in both Britain and America remains auspicious
By Max King Published